ARMP:NYE-Armata Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 2.4

Change

0.00 (0.00)%

Market Cap

USD 0.09B

Volume

0.01M

Analyst Target

USD 7.75
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc. Address: 5005 McConnell Avenue, Los Angeles, CA, United States, 90066

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NVO Novo Nordisk A/S

N/A

USD 609.93B
BHVN Biohaven Pharmaceutical Holdin..

N/A

USD 3.82B
RCUS Arcus Biosciences Inc

N/A

USD 1.64B
NUVB Nuvation Bio Inc

N/A

USD 1.03B
ANRO Alto Neuroscience, Inc.

N/A

USD 0.37B
DNA Ginkgo Bioworks Holdings

N/A

USD 0.35B
ADCT ADC Therapeutics SA

N/A

USD 0.32B
CYBN Cybin Inc

N/A

USD 0.15B
ANVS Annovis Bio Inc

N/A

USD 0.11B
CVM CEL-SCI Corp

N/A

USD 0.08B

ETFs Containing ARMP

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -25.93% 47% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.93% 47% F 7% C-
Trailing 12 Months  
Capital Gain -10.45% 61% D- 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.45% 61% D- 12% F
Trailing 5 Years  
Capital Gain -42.17% 62% D 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.17% 62% D 10% F
Average Annual (5 Year Horizon)  
Capital Gain 7.27% 70% C- 62% D
Dividend Return 7.27% 67% D+ 55% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 52.57% 58% F 17% F
Risk Adjusted Return 13.82% 67% D+ 34% F
Market Capitalization 0.09B 67% D+ 25% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector